Viewing Study NCT02004769

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:13 PM
Ignite Modification Date: 2026-02-22 @ 7:26 AM
Study NCT ID: NCT02004769
Status: COMPLETED
Last Update Posted: 2016-11-18
First Post: 2013-09-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Sponsor: Sun Yat-sen University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Stomach Neoplasms View
None Neoplasms Metastasis View
None ERBB2 Gene Amplification View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic gastric or gastro-esophageal junction cancer View
None Trastuzumab View
None HER2-positive View
None Capecitabine View
None Docetaxel View
None First-line therapy View